文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

治疗剂量肝素与标准预防或中等剂量肝素在高危COVID-19住院患者血栓预防中的疗效与安全性:HEP-COVID随机临床试验

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2021-01-01
一句话结论在高危COVID-19住院患者中,治疗剂量低分子肝素较机构标准预防或中等剂量肝素减少主要血栓栓塞和死亡,但ICU患者未见获益。

HEP-COVID多中心随机临床试验纳入257例D-二聚体超过正常上限4倍或脓毒症诱导凝血病评分≥4的COVID-19住院患者,比较治疗剂量依诺肝素与机构标准预防或中等剂量肝素。治疗剂量组主要疗效终点(静脉血栓栓塞、动脉血栓栓塞或全因死亡)发生率28.7%,标准剂量组41.9%(RR 0.68,95%CI 0.49-0.96,P=0.03),血栓栓塞事件减少(10.9% vs 29.0%,RR 0.37,95%CI 0.21-0.66,P<0.001)。大出血发生率两组无显著差异(4.7% vs 1.6%,RR 2.88,95%CI 0.59-14.02,P=0.17)。非ICU患者主要终点降低(16.7% vs 36.1%,RR 0.46,95%CI 0.27-0.81,P=0.004),ICU患者未见获益(51.1% vs 55.3%,RR 0.92,95%CI 0.62-1.39,P=0.71)。

要点

  • 高危COVID-19住院患者(D-二聚体>4倍正常上限或脓毒症诱导凝血病评分≥4)中,治疗剂量依诺肝素较标准预防或中等剂量肝素降低主要疗效终点(28.7% vs 41.9%,RR 0.68,95%CI 0.49-0.96)。
  • 治疗剂量依诺肝素降低血栓栓塞事件(10.9% vs 29.0%,RR 0.37,95%CI 0.21-0.66,P<0.001)。
  • 大出血发生率治疗剂量组4.7% vs 标准剂量组1.6%,差异未达统计学显著(RR 2.88,95%CI 0.59-14.02,P=0.17)。
  • 非ICU患者主要疗效终点降低(16.7% vs 36.1%,RR 0.46,95%CI 0.27-0.81,P=0.004),ICU患者未见获益(51.1% vs 55.3%,RR 0.92,95%CI 0.62-1.39,P=0.71)。
  • 治疗剂量依诺肝素用法:肌酐清除率≥30 mL/min/1.73 m²时1 mg/kg皮下注射每日两次;肌酐清除率15-29 mL/min/1.73 m²时0.5 mg/kg每日两次,贯穿住院期间。

适用人群与场景

  • 纳入:成人COVID-19住院患者,D-二聚体超过正常上限4倍或脓毒症诱导凝血病评分≥4。
  • 场景:美国12个学术中心住院患者,随机时按ICU或非ICU状态分层;83例(32.8%)为ICU级别护理。

诊断标准与关键阈值

  • 纳入标准之一:D-二聚体水平超过正常上限4倍。
  • 纳入标准之一:脓毒症诱导凝血病评分≥4。
  • 249例(98.4%)基于D-二聚体升高符合纳入标准。

处置流程与药物剂量

  • 治疗剂量组:依诺肝素1 mg/kg皮下注射每日两次,适用于肌酐清除率≥30 mL/min/1.73 m²的患者,贯穿住院期间。
  • 治疗剂量组:依诺肝素0.5 mg/kg皮下注射每日两次,适用于肌酐清除率15-29 mL/min/1.73 m²的患者,贯穿住院期间。
  • 对照组:机构标准预防剂量或中等剂量低分子肝素或普通肝素。
  • 随机时按ICU或非ICU状态分层。

研究设计与关键结果

  • 多中心随机临床试验,257例随机,253例纳入分析;平均年龄66.7岁(SD 14.0),男性136例(53.8%),女性117例(46.2%)。
  • 主要疗效终点(30±2天静脉血栓栓塞、动脉血栓栓塞或全因死亡):标准剂量组52/124例(41.9%)vs 治疗剂量组37/129例(28.7%),RR 0.68(95%CI 0.49-0.96,P=0.03)。
  • 标准剂量组主要终点构成:VTE 28.2%、ATE 3.2%、死亡25.0%;治疗剂量组:VTE 11.7%、ATE 3.2%、死亡19.4%。
  • 血栓栓塞事件:标准剂量组29.0% vs 治疗剂量组10.9%,RR 0.37(95%CI 0.21-0.66,P<0.001)。
  • 主要安全终点大出血:标准剂量组1.6% vs 治疗剂量组4.7%,RR 2.88(95%CI 0.59-14.02,P=0.17)。
  • 非ICU患者主要疗效终点:标准剂量组36.1% vs 治疗剂量组16.7%,RR 0.46(95%CI 0.27-0.81,P=0.004)。
  • ICU患者主要疗效终点:标准剂量组55.3% vs 治疗剂量组51.1%,RR 0.92(95%CI 0.62-1.39,P=0.71)。

证据类型、等级与局限

  • 证据类型:多中心随机临床试验(HEP-COVID,ClinicalTrials.gov NCT04401293)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在D-二聚体显著升高的COVID-19住院患者中,治疗剂量低分子肝素较机构标准肝素血栓预防减少主要血栓栓塞和死亡。
  • 作者认为,该治疗效应在ICU患者中未见。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Hospitalized patients with COVID-19 are at risk for venous and arterial thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown.

OBJECTIVE: To evaluate the effects of therapeutic-dose low-molecular-weight heparin (LMWH) vs institutional standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: The HEP-COVID multicenter randomized clinical trial recruited hospitalized adult patients with COVID-19 with D-dimer levels more than 4 times the upper limit of normal or sepsis-induced coagulopathy score of 4 or greater from May 8, 2020, through May 14, 2021, at 12 academic centers in the US.

INTERVENTIONS: Patients were randomized to institutional standard prophylactic or intermediate-dose LMWH or unfractionated heparin vs therapeutic-dose enoxaparin, 1 mg/kg subcutaneous, twice daily if creatinine clearance was 30 mL/min/1.73 m2 or greater (0.5 mg/kg twice daily if creatinine clearance was 15-29 mL/min/1.73 m2) throughout hospitalization. Patients were stratified at the time of randomization based on intensive care unit (ICU) or non-ICU status.

MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was venous thromboembolism (VTE), arterial thromboembolism (ATE), or death from any cause, and the principal safety outcome was major bleeding at 30 ± 2 days. Data were collected and adjudicated locally by blinded investigators via imaging, laboratory, and health record data.

RESULTS: Of 257 patients randomized, 253 were included in the analysis (mean [SD] age, 66.7 [14.0] years; men, 136 [53.8%]; women, 117 [46.2%]); 249 patients (98.4%) met inclusion criteria based on D-dimer elevation and 83 patients (32.8%) were stratified as ICU-level care. There were 124 patients (49%) in the standard-dose vs 129 patients (51%) in the therapeutic-dose group. The primary efficacy outcome was met in 52 of 124 patients (41.9%) (28.2% VTE, 3.2% ATE, 25.0% death) with standard-dose heparins vs 37 of 129 patients (28.7%) (11.7% VTE, 3.2% ATE, 19.4% death) with therapeutic-dose LMWH (relative risk [RR], 0.68; 95% CI, 0.49-0.96; P = .03), including a reduction in thromboembolism (29.0% vs 10.9%; RR, 0.37; 95% CI, 0.21-0.66; P < .001). The incidence of major bleeding was 1.6% with standard-dose vs 4.7% with therapeutic-dose heparins (RR, 2.88; 95% CI, 0.59-14.02; P = .17). The primary efficacy outcome was reduced in non-ICU patients (36.1% vs 16.7%; RR, 0.46; 95% CI, 0.27-0.81; P = .004) but not ICU patients (55.3% vs 51.1%; RR, 0.92; 95% CI, 0.62-1.39; P = .71).

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, therapeutic-dose LMWH reduced major thromboembolism and death compared with institutional standard heparin thromboprophylaxis among inpatients with COVID-19 with very elevated D-dimer levels. The treatment effect was not seen in ICU patients.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04401293.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021. PMID: 34617959. doi:10.1001/jamainternmed.2021.6203

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。